No label defined (Q33329)
Jump to navigation
Jump to search
No description defined
- Operative Complications, Vaginal Bleeding, and Practice Considerations for Patients on Testosterone Undergoing Gender-Affirming Hysterectomy.
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
No description defined |
|
Statements
To evaluate operative complications and healthcare utilization in transgender patients on testosterone undergoing minimally invasive gender-affirming hysterectomy compared to control patients. (English)
STUDY OBJECTIVE (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
We performed a retrospective cohort study. (English)
DESIGN (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Operative reports were used to gather information on intraoperative complications. (English)
DESIGN (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
We collected information on postoperative complications, electronic medical record (EMR) messages, phone calls, emergency department utilization, and clinic visits through a 90-day postoperative period. (English)
DESIGN (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Healthcare utilization reasons were categorized as vaginal bleeding, pain, vaginal discharge, dysuria, urinary retention, bowel concern, incision concern, or other. (English)
DESIGN (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Tertiary care academic medical center. (English)
SETTING (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Patients aged 18 to 55 who underwent a benign minimally invasive hysterectomy with or without oophorectomy performed between January 2014 and December 2022. (English)
PATIENTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
The testosterone-using cohort consisted of patients who had a gender identity of male, transgender male, genderqueer, or nonbinary with documented testosterone use prior to surgery (n = 88). (English)
PATIENTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
The control cohort consisted of patients who identified as female, genderqueer, or nonbinary with no documented testosterone use (n = 242). (English)
PATIENTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Not applicable. (English)
INTERVENTIONS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Patients using testosterone were younger, had a lower body mass index, lower American Society of Anesthesiologists class, and were more likely to be nulliparous. (English)
MEASUREMENTS AND MAIN RESULTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
The median time patients used testosterone was 2.5 years (1.5-5.0). (English)
MEASUREMENTS AND MAIN RESULTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Patients on testosterone are at increased risk of intraoperative perineal lacerations requiring repair (RR 3.3, CI 95% [1.03-10.5]). (English)
MEASUREMENTS AND MAIN RESULTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
A higher number of patients on testosterone reported vaginal bleeding via EMR message or phone call (RR 1.74 CI 95% [1.1-2.7]) compared to controls. (English)
MEASUREMENTS AND MAIN RESULTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
No difference in reasons for emergency department visits was noted. (English)
MEASUREMENTS AND MAIN RESULTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
The use of postoperative vaginal estrogen started at the postoperative visit was more frequent in the testosterone-using patients (7 [8.0%] vs 4 [1.7%], p = .01). (English)
MEASUREMENTS AND MAIN RESULTS (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
This study demonstrates that testosterone use preoperatively may increase risk of intraoperative vaginal laceration requiring repair. (English)
CONCLUSION (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Testosterone use also correlates with increased reports of vaginal bleeding through EMR message, phone call, and clinic visit. (English)
CONCLUSION (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
These results contribute new evidence to include in preoperative counseling and support existing evidence surrounding the safety of gender-affirming hysterectomy. (English)
CONCLUSION (English)
Copyright © 2024 AAGL. Published by Elsevier Inc. All rights reserved. (English)
2024
Christine (English)
Pando (English)
C
Leah R (English)
Gerlach (English)
LR
Sai Alekha (English)
Challa (English)
SA
Amy Y (English)
Pan (English)
AY
Jessica (English)
Francis (English)
J
5 October 2024
5 October 2024
Conflict of Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. (English)